Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2025-11-17 Major Shareholding Noti…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Franchissement de seuil
Major Shareholding Notification Classification · 100% confidence The document is a formal notification of a threshold crossing ('Déclaration de franchissement de seuil') filed under Article L. 233-7 of the French Commercial Code. It details that The Goldman Sachs Group, Inc. has crossed below the 5% voting rights threshold in the company NANOBIOTIX. This type of regulatory disclosure regarding significant shareholding changes is classified as a Major Shareholding Notification.
2025-11-17 French
Franchissements de seuil
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the AMF (Autorité des marchés financiers) regarding 'Déclarations de franchissements de seuil' (threshold crossing declarations). It details specific instances where The Goldman Sachs Group, Inc. crossed the 5% voting rights threshold in the company NANOBIOTIX. This type of regulatory disclosure regarding significant shareholding changes is classified as a Major Shareholding Notification.
2025-11-17 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a press release titled 'VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY'. It explicitly references French Commercial Code articles L.233-8 II and AMF General Regulation 223-16, which mandate the disclosure of the total number of shares and voting rights. This type of disclosure is a standard regulatory requirement for listed companies in France to inform the market of their capital structure and voting rights, which falls under the category of Regulatory Filings (RNS) as it does not fit into specific categories like 'Major Shareholding Notification' (which tracks external investors) or 'Share Issue' (which tracks specific capital changes).
2025-11-14 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 95% confidence The document is a monthly disclosure of the total number of voting rights and shares composing the share capital, as required by French commercial law (Article L.233-8 II) and AMF regulations. This type of filing is a standard regulatory disclosure regarding capital structure and voting rights, which falls under the 'Regulatory Filings' category as it does not represent a specific share issuance event (SHA) or a major shareholding notification (MRQ) by an external party.
2025-11-14 French
NANOBIOTIX annonce les avancées de sa plateforme de nanoprimer Curadigm avec une mise à jour des plans de développement pour son pipeline interne et des collaborations externes
Regulatory Filings Classification · 95% confidence The document is a press release from Nanobiotix announcing updates on its 'Curadigm' nanoprimer platform, including new patent filings, preclinical data, and business development progress. It is a corporate announcement regarding company strategy and R&D milestones rather than a formal financial report, audit, or regulatory filing. As it provides specific updates on company activities and pipeline development, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-11-13 French
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
Regulatory Filings Classification · 97% confidence The document is a press release issued by Nanobiotix regarding advancements in its 'Curadigm Nanoprimer' platform, including new patent filings, preclinical data presentations, and business development updates. It does not constitute a formal financial report (like a 10-K or IR), a transcript, or a regulatory filing of a specific form type. As it is a general corporate announcement regarding business operations and technology development, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2025-11-13 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.